Efficacy and Safety of Pemafibrate in Patients with Hypertriglyceridemia after Switching from Other Fibrates

Abstract

Objective: To investigate the effects of switching from other fibrates to pemafibrate on lipid and liver/renal function in patients with hypertriglyceridemia.Methods: A retrospective study was conducted using the medical records of 31 patients with hypertriglyceridemiawho were switched from other fibrates to pemafibrate. Changes in triglyceride (TG), high-density lipoproteincholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), alanineaminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), serum creatinine, estimated glomerular filtration rate(eGFR), creatine kinase (CK), and uric acid (UA) levels were investigated.Results: Switching from other fibrates to pemafibrate did not significantly improve plasma TG, HDL-C, or LDL-Clevels. However, plasma TG levels did show a significant reduction in the subgroup with hypertriglyceridemia (TG≥ 150 mg/dL). Switching from other fibrates to pemafibrate significantly improved ALT, γ-GTP, serum creatinine,eGFR, and CK levels. There was no significant change in UA levels.Conclusion: Switching from other fibrates to pemafibrate significantly improved liver and renal function. In addition, plasma TG levels were also significantly improved in patients with hypertriglyceridemia (TG ≥ 150 mg/dL).